- Home
- OUST vs SGP Comparison
OUST vs SGP Comparison
Compare OUST & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OUST | SGP |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 932.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OUST | SGP |
|---|---|---|
| Price | $19.50 | $22.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $39.25 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.9M | 106.1K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.22 | N/A |
| Revenue Next Year | $37.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.34 | $21.29 |
| 52 Week High | $41.65 | $30.56 |
Technical Indicators
Market Signals| Indicator | OUST | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 37.86 |
| Support Level | $17.80 | $21.29 |
| Resistance Level | $21.45 | $29.83 |
| Average True Range (ATR) | 1.39 | 2.10 |
| MACD | -0.22 | -0.27 |
| Stochastic Oscillator | 50.67 | 12.52 |
Price Performance
Historical ComparisonAbout OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.